Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
ATLANTA, April 14, 2016 -- Aviragen Therapeutics, Inc., (NASDAQ:AVIR), formerly Biota Pharmaceuticals, Inc., today announced that Joseph Patti, PhD, President & CEO of Aviragen Therapeutics, will participate in a panel discussion titled, “Notable Emerging Anti-Viral Agents” as part of the FBR & Co. New Prescriptions: Innovation in the Treatment of Diseases and Infections conference.
The panel discussion will take place at 10:30am ET on Wednesday, April 20, 2016 at the JW Marriott Essex House in New York.
About Aviragen Therapeutics, Inc.
Aviragen Therapeutics is focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three product candidates in active clinical development: These include vapendavir, an oral treatment for human rhinovirus upper (HRV) respiratory infections in moderate-to-severe asthmatics currently being evaluated in the Phase 2b SPIRITUS trial; BTA585, an oral fusion protein inhibitor that has received Fast Track designation by the U.S. FDA, in Phase 2 development for the treatment and prevention of respiratory syncytial virus (RSV) infections; and BTA074, a topical antiviral treatment in Phase 2 development for condyloma caused by human papillomavirus types 6 & 11. For additional information about the Company, please visit www.aviragentherapeutics.com.
Contacts: Mark Colonnese Executive Vice President and Chief Financial Officer Aviragen Therapeutics, Inc. (678) 221-3381 [email protected] Beth DelGiacco Stern Investor Relations, Inc. (212) 362-1200 [email protected]
